Related Experiment Videos
Feasibility of chemosensitivity testing in soft tissue sarcomas
Marcus Lehnhardt1, Thomas Muehlberger, Cornelius Kuhnen
1Department of Plastic Surgery, Burn Center, Hand surgery, Sarcoma Reference Center, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bürkle-de-la Camp Platz 1, 44789 Bochum, Germany. marcus.lehnhardt@rub.de.
World Journal of Surgical Oncology
|April 20, 2005
Summary
Chemosensitivity testing in soft tissue sarcomas shows varied drug responses based on tumor type and recurrence. Actinomycin D and doxorubicin combinations offer high sensitivity, guiding personalized chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Soft tissue sarcomas are rare malignancies with variable behavior influenced by histology and location.
- Current standard treatment involves surgery and radiotherapy; chemotherapy's role is limited and often experimental.
- Established chemotherapeutic agents like doxorubicin, epirubicin, and ifosfamide show response rates over 20%.
Purpose of the Study:
- To investigate the chemosensitivity of soft tissue sarcomas to seven single chemotherapy agents and four combinations.
- To evaluate the feasibility of an in-vitro ATP-based testing system for assessing sarcoma chemosensitivity.
- To identify potential discrepancies in drug efficacy across different sarcoma subtypes and tumor presentations.
Main Methods:
- An ATP-based luminescence assay (luciferin-luciferase) was used to test the chemosensitivity of 50 soft tissue sarcoma samples.
- Individual chemosensitivity indices were determined for each chemotherapy agent and combination tested.
- Tumor samples were analyzed for sensitivity to single agents and specific drug combinations.
Main Results:
- Chemosensitivity varied significantly based on histological subtypes and the degree of cellular dedifferentiation.
- Actinomycin D demonstrated the highest sensitivity as a single agent (74% high sensitivity).
- Combinations of actinomycin D with ifosfamide (76% high sensitivity) and doxorubicin with ifosfamide (72% high sensitivity) showed promising efficacy.
Conclusions:
- In-vitro chemosensitivity testing is a viable method for soft tissue sarcomas, enabling the creation of drug sensitivity profiles.
- Significant differences in drug efficacy exist among sarcoma subtypes and between primary and recurrent tumors.
- Current treatment protocols do not account for these individual chemosensitivity variations, highlighting a need for personalized approaches.